AF267

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563382

CAS#: 168818-83-5

Description: AF267 is a M1 muscarinic agonist that acts by restoring cognitive impairments.

Chemical Structure

img
AF267
CAS# 168818-83-5
Instruction

Theoretical Analysis

MedKoo Cat#: 563382
Name: AF267
CAS#: 168818-83-5
Chemical Formula: C10H18N2OS
Exact Mass: 214.11
Molecular Weight: 214.320
Elemental Analysis: C, 56.04; H, 8.47; N, 13.07; O, 7.46; S, 14.96

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: AF267; AF-267; AF 267; (±)-AF 267; (±) AF 267; (±)AF 267;

IUPAC/Chemical Name: 2-Ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one

InChi Key: PHOZOHFUXHPOCK-UHFFFAOYSA-N

InChi Code: InChI=1S/C10H18N2OS/c1-3-8-9(13)11-10(14-8)4-6-12(2)7-5-10/h8H,3-7H2,1-2H3,(H,11,13)

SMILES Code: O=C1C(CC)SC2(CCN(C)CC2)N1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 214.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Svingen GFT, Zuo H, Ueland PM, Seifert R, Løland KH, Pedersen ER, Schuster PM, Karlsson T, Tell GS, Schartum-Hansen H, Olset H, Svenningsson M, Strand E, Nilsen DW, Nordrehaug JE, Dhar I, Nygård O. Increased plasma trimethylamine-N-oxide is associated with incident atrial fibrillation. Int J Cardiol. 2018 Sep 15;267:100-106. doi: 10.1016/j.ijcard.2018.04.128. PubMed PMID: 29957250.

2: Trakman GL, Forsyth A, Hoye R, Belski R. Development and validation of a brief general and sports nutrition knowledge questionnaire and assessment of athletes' nutrition knowledge. J Int Soc Sports Nutr. 2018 Apr 19;15:17. doi: 10.1186/s12970-018-0223-1. eCollection 2018. PubMed PMID: 29713248; PubMed Central PMCID: PMC5907737.

3: Hoskins MH, Patel AM, DeLurgio DB. Left Atrial Appendage Occlusion, Shared Decision-Making, and Comprehensive Atrial Fibrillation Management. Interv Cardiol Clin. 2018 Apr;7(2):267-283. doi: 10.1016/j.iccl.2017.12.006. Review. PubMed PMID: 29526294.

4: Yoshida T, Uchino S, Yokota T, Fujii T, Uezono S, Takinami M. The impact of sustained new-onset atrial fibrillation on mortality and stroke incidence in critically ill patients: A retrospective cohort study. J Crit Care. 2018 Apr;44:267-272. doi: 10.1016/j.jcrc.2017.11.040. Epub 2017 Dec 1. PubMed PMID: 29220756.

5: Pedro B, Dukes-McEwan J, Oyama MA, Kraus MS, Gelzer AR. Retrospective Evaluation of the Effect of Heart Rate on Survival in Dogs with Atrial Fibrillation. J Vet Intern Med. 2018 Jan;32(1):86-92. doi: 10.1111/jvim.14896. Epub 2017 Dec 4. PubMed PMID: 29205499; PubMed Central PMCID: PMC5787213.

6: Bun SS, Delassi T, Latcu DG, El Jamili M, Ayari A, Errahmouni A, Berte B, Saoudi N. A comparison between multipolar mapping and conventional mapping of atrial tachycardias in the context of atrial fibrillation ablation. Arch Cardiovasc Dis. 2018 Jan;111(1):33-40. doi: 10.1016/j.acvd.2017.04.005. Epub 2017 Sep 18. PubMed PMID: 28927960.

7: Kodama A, Koyama A, Sugimoto M, Niimi K, Banno H, Komori K. Association Between Preoperative Frailty and Mortality in Patients With Critical Limb Ischemia Following Infrainguinal Bypass Surgery　- Usefulness of the Barthel Index. Circ J. 2017 Dec 25;82(1):267-274. doi: 10.1253/circj.CJ-17-0369. Epub 2017 Aug 23. PubMed PMID: 28835590.

8: Ribeiro de Ávila V, Bento T, Gomes W, Leitão J, Fortuna de Sousa N. Functional Outcomes and Quality of Life After Ankle Fracture Surgically Treated: A Systematic Review. J Sport Rehabil. 2018 May 1;27(3):274-283. doi: 10.1123/jsr.2016-0199. Epub 2018 Jun 1. PubMed PMID: 28338395.

9: Marcos EG, Geelhoed B, Van Der Harst P, Bakker SJL, Gansevoort RT, Hillege HL, Van Gelder IC, Rienstra M. Relation of renal dysfunction with incident atrial fibrillation and cardiovascular morbidity and mortality: The PREVEND study. Europace. 2017 Dec 1;19(12):1930-1936. doi: 10.1093/europace/euw373. PubMed PMID: 28108549.

10: Zhao Y, Yang Y, Tang X, Yu X, Zhang L, Xiao H. New oral anticoagulants compared to warfarin for perioperative anticoagulation in patients undergoing atrial fibrillation catheter ablation: a meta-analysis of continuous or interrupted new oral anticoagulants during ablation compared to interrupted or continuous warfarin. J Interv Card Electrophysiol. 2017 Apr;48(3):267-282. doi: 10.1007/s10840-016-0221-7. Epub 2017 Jan 12. Review. PubMed PMID: 28078536.

11: Masbah N, Macleod MJ. The cost savings of newer oral anticoagulants in atrial fibrillation-related stroke prevention. Int J Clin Pharmacol Ther. 2017 Mar;55(3):220-230. doi: 10.5414/CP202651. PubMed PMID: 28025962.

12: Frankova A, Malik J, Drabek O, Szakova J, Sperlingova I, Kloucek P, Novy P, Tejnecky V, Landa P, Leuner O, Kokoska L. In Vitro Digestibility of Aluminum from Hibiscus sabdariffa Hot Watery Infusion and Its Concentration in Urine of Healthy Individuals. Biol Trace Elem Res. 2016 Dec;174(2):267-273. Epub 2016 Apr 23. PubMed PMID: 27107884.

13: Tailachidis P, Tsimtsiou Z, Galanis P, Theodorou M, Kouvelas D, Athanasakis K. The Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) questionnaire: cultural adaptation and validation of the Greek version. Hippokratia. 2016 Oct-Dec;20(4):264-267. PubMed PMID: 29416298; PubMed Central PMCID: PMC5788239.

14: Hayase N, Yamamoto M, Asada T, Isshiki R, Yahagi N, Doi K. Association of Heart Rate with N-Terminal Pro-B-Type Natriuretic Peptide in Septic Patients: A Prospective Observational Cohort Study. Shock. 2016 Dec;46(6):642-648. PubMed PMID: 27380528.

15: Wang J, Yang J, Yang Z, Lu X, Jin C, Cheng L, Wu N. RbAp48, a novel inhibitory factor that regulates the transcription of human immunodeficiency virus type 1. Int J Mol Med. 2016 Jul;38(1):267-74. doi: 10.3892/ijmm.2016.2598. Epub 2016 May 19. PubMed PMID: 27222146.

16: Faza NN, Mentias A, Parashar A, Chaudhury P, Barakat AF, Agarwal S, Wayangankar S, Ellis SG, Murat Tuzcu E, Kapadia SR. Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions. Catheter Cardiovasc Interv. 2017 Feb 1;89(2):E64-E74. doi: 10.1002/ccd.26574. Epub 2016 May 24. PubMed PMID: 27220088.

17: Ferguson C, Inglis SC, Newton PJ, Middleton S, Macdonald PS, Davidson PM. Multi-morbidity, frailty and self-care: important considerations in treatment with anticoagulation drugs. Outcomes of the AFASTER study. Eur J Cardiovasc Nurs. 2017 Feb;16(2):113-124. doi: 10.1177/1474515116642604. Epub 2016 Jul 7. PubMed PMID: 27036952.

18: Vlachos K, Letsas KP, Korantzopoulos P, Liu T, Georgopoulos S, Bakalakos A, Karamichalakis N, Xydonas S, Efremidis M, Sideris A. Prediction of atrial fibrillation development and progression: Current perspectives. World J Cardiol. 2016 Mar 26;8(3):267-76. doi: 10.4330/wjc.v8.i3.267. Review. PubMed PMID: 27022458; PubMed Central PMCID: PMC4807315.

19: He X, Zhou Y, Chen Y, Wu L, Huang Y, He J. Left atrial posterior wall isolation reduces the recurrence of atrial fibrillation: a meta-analysis. J Interv Card Electrophysiol. 2016 Sep;46(3):267-74. doi: 10.1007/s10840-016-0124-7. Epub 2016 Mar 12. Review. PubMed PMID: 26971331.

20: Al-Khalili F, Lindström C, Benson L. The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic. Curr Med Res Opin. 2016;32(4):779-85. doi: 10.1185/03007995.2016.1142432. Epub 2016 Feb 10. PubMed PMID: 26765366.